Validation of a Hematopoietic Cell Transplant - Composite Risk (HCT-CR) Model for Post Transplant Survival Prediction in Patients with Hematologic Malignancies.

CONCLUSIONS: The HCT-CR can be effectively used to predict post-transplant survival in patients with various hematologic malignancies. This composite model can identify patients who will benefit the most from transplantation and helps physicians in making decisions regarding post-transplant therapy to improve outcomes.
PMID: 32019857 [PubMed - as supplied by publisher]

Source: Clinical Cancer Research - February 3, 2020 Category: Cancer & Oncology Authors: Ciurea SO, Kongtim P, Hasan O, Ramos Perez JM, Torres J, Rondon G, Champlin RE Tags: Clin Cancer Res Source Type: research